Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
- Author
- COSTABEL, Ulrich1 ; BENDSTRUP, Elisabeth2 ; MOLINA-MOLINA, Maria11 ; NORDLIND, Klas12 ; SARAFIDIS, Alexandre13 ; VANCHERI, Carlo14 ; COTTIN, Vincent3 ; DEWINT, Pieter4 ; EGAN, Jim J. J5 ; FERGUSON, James6 ; GROVES, Richard7 ; HELLSTRÖM, Per M8 ; KREUTER, Michael9 ; MAHER, Toby M10
[1] Department of Pneumology/Allergology, Ruhrlandklinik, University Hospital, University Duisburg-Essen, Essen, Germany
[2] Department of Respiratory Medicine and Allergology, Aarhus University Hospital, Aarhus, Denmark
[3] Hôpital Louis Pradel, Service de Pneumologie, Centre de Reference National des Maladies Pulmonaires Rares, Université Claude Bernard Lyon 1, UMR754, Lyon, France
[4] Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, Netherlands
[5] Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland
[6] Department of Dermatology, Ninewells Hospital, Dundee, United Kingdom
[7] Division of Genetics and Molecular Medicine, St. John's Institute of Dermatology, King's College London School of Medicine, London, United Kingdom
[8] Department of Medical Sciences, Gastroenterology and Hepatology, Uppsala University, Uppsala, Sweden
[9] Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg and Translational Lung Research Centre Heidelberg, Heidelberg, Germany
[10] Interstitial Lung Disease Unit, Royal Brompton Hospital, London, United Kingdom
[11] Unidad Funcional de Intersticio Pulmonar, Servicio de Neumología, Hospital Universitario de Bellvitge, IDIBELL, CIBERES, Hospitalet de Llobregat, Barcelona, Spain
[12] Dermatology and Venerology Unit, Department of Medicine, Solna, Karolinska University Hospital, Stockholm, Sweden
[13] Department of Gastroenterology, Parc Leopold Hospital (CHIREC), Brussels, Belgium
[14] Regional Centre for Rare Lung Disease, University of Catania, Catania, Italy - Source
Advances in therapy. 2014, Vol 31, Num 4, pp 375-391, 17 p ; ref : 38 ref
- ISSN
- 0741-238X
- Scientific domain
- Pharmacology drugs
- Publisher
- Springer, New York, NY
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- Adverse event management Expert opinion Gastrointestinal events Idiopathic pulmonary fibrosis Photosensitivity Pirfenidone Respiratory Safety Skin-related events
- Keyword (fr)
- Appareil respiratoire Conduite à tenir Effet secondaire Estomac Fibrose des poumons Gastrointestinal Homme Idiopathique Immunodépresseur Intestin Peau Photosensibilité Pirfénidone Recommandation Toxicité Traitement Appareil digestif Pathologie de l'appareil respiratoire Pathologie de la peau Pathologie des poumons
- Keyword (en)
- Respiratory system Clinical management Secondary effect Stomach Pulmonary fibrosis Gastrointestinal Human Idiopathic Immunosuppressive agent Gut Skin Photosensitivity Pirfenidone Recommendation Toxicity Treatment Digestive system Respiratory disease Skin disease Lung disease
- Keyword (es)
- Aparato respiratorio Actitud médica Efecto secundario Estómago Fibrosis pulmonar Gastrointestinal Hombre Idiopático Inmunodepresor Intestino Piel Fotosensibilidad Pirfenidona Recomendación Toxicidad Tratamiento Aparato digestivo Aparato respiratorio patología Piel patología Pulmón patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02D Respiratory system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11D Respiratory system : syndromes and miscellaneous diseases
- Discipline
- Pharmacological treatments Pulmonology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 28438294
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s12325-014-0112-1 
https://dx.doi.org/10.1007/s12325-014-0112-1
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s12325-014-0112-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Advances in therapy\";s:9:\"\u0000*\u0000stitle\";s:9:\"Adv. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"375\";s:8:\"\u0000*\u0000epage\";s:3:\"391\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0741-238X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"COSTABEL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:20:\"BENDSTRUP, Elisabeth\";i:1;s:20:\"MOLINA-MOLINA, Maria\";i:2;s:14:\"NORDLIND, Klas\";i:3;s:20:\"SARAFIDIS, Alexandre\";i:4;s:15:\"VANCHERI, Carlo\";i:5;s:15:\"COTTIN, Vincent\";i:6;s:14:\"DEWINT, Pieter\";i:7;s:14:\"EGAN, Jim J. J\";i:8;s:15:\"FERGUSON, James\";i:9;s:15:\"GROVES, Richard\";i:10;s:17:\"HELLSTR\u00d6M, Per M\";i:11;s:16:\"KREUTER, Michael\";i:12;s:13:\"MAHER, Toby M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"17\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s12325-014-0112-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Advances in therapy\";s:9:\"\u0000*\u0000stitle\";s:9:\"Adv. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"375\";s:8:\"\u0000*\u0000epage\";s:3:\"391\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0741-238X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"COSTABEL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:20:\"BENDSTRUP, Elisabeth\";i:1;s:20:\"MOLINA-MOLINA, Maria\";i:2;s:14:\"NORDLIND, Klas\";i:3;s:20:\"SARAFIDIS, Alexandre\";i:4;s:15:\"VANCHERI, Carlo\";i:5;s:15:\"COTTIN, Vincent\";i:6;s:14:\"DEWINT, Pieter\";i:7;s:14:\"EGAN, Jim J. J\";i:8;s:15:\"FERGUSON, James\";i:9;s:15:\"GROVES, Richard\";i:10;s:17:\"HELLSTR\u00d6M, Per M\";i:11;s:16:\"KREUTER, Michael\";i:12;s:13:\"MAHER, Toby M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"17\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s12325-014-0112-1\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s12325-014-0112-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Advances in therapy\";s:9:\"\u0000*\u0000stitle\";s:9:\"Adv. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"375\";s:8:\"\u0000*\u0000epage\";s:3:\"391\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0741-238X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"COSTABEL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:20:\"BENDSTRUP, Elisabeth\";i:1;s:20:\"MOLINA-MOLINA, Maria\";i:2;s:14:\"NORDLIND, Klas\";i:3;s:20:\"SARAFIDIS, Alexandre\";i:4;s:15:\"VANCHERI, Carlo\";i:5;s:15:\"COTTIN, Vincent\";i:6;s:14:\"DEWINT, Pieter\";i:7;s:14:\"EGAN, Jim J. J\";i:8;s:15:\"FERGUSON, James\";i:9;s:15:\"GROVES, Richard\";i:10;s:17:\"HELLSTR\u00d6M, Per M\";i:11;s:16:\"KREUTER, Michael\";i:12;s:13:\"MAHER, Toby M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"17\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s12325-014-0112-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Advances in therapy\";s:9:\"\u0000*\u0000stitle\";s:9:\"Adv. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"375\";s:8:\"\u0000*\u0000epage\";s:3:\"391\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0741-238X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"COSTABEL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:20:\"BENDSTRUP, Elisabeth\";i:1;s:20:\"MOLINA-MOLINA, Maria\";i:2;s:14:\"NORDLIND, Klas\";i:3;s:20:\"SARAFIDIS, Alexandre\";i:4;s:15:\"VANCHERI, Carlo\";i:5;s:15:\"COTTIN, Vincent\";i:6;s:14:\"DEWINT, Pieter\";i:7;s:14:\"EGAN, Jim J. J\";i:8;s:15:\"FERGUSON, James\";i:9;s:15:\"GROVES, Richard\";i:10;s:17:\"HELLSTR\u00d6M, Per M\";i:11;s:16:\"KREUTER, Michael\";i:12;s:13:\"MAHER, Toby M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"17\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s12325-014-0112-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:9:\"\u0000*\u0000jtitle\";s:19:\"Advances in therapy\";s:9:\"\u0000*\u0000stitle\";s:9:\"Adv. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"375\";s:8:\"\u0000*\u0000epage\";s:3:\"391\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0741-238X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"COSTABEL\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:20:\"BENDSTRUP, Elisabeth\";i:1;s:20:\"MOLINA-MOLINA, Maria\";i:2;s:14:\"NORDLIND, Klas\";i:3;s:20:\"SARAFIDIS, Alexandre\";i:4;s:15:\"VANCHERI, Carlo\";i:5;s:15:\"COTTIN, Vincent\";i:6;s:14:\"DEWINT, Pieter\";i:7;s:14:\"EGAN, Jim J. J\";i:8;s:15:\"FERGUSON, James\";i:9;s:15:\"GROVES, Richard\";i:10;s:17:\"HELLSTR\u00d6M, Per M\";i:11;s:16:\"KREUTER, Michael\";i:12;s:13:\"MAHER, Toby M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:118:\"Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"17\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
